Items

Efficacy and Safety of Once Monthly Ibandronate Treatment in Patients with Reduced Bone Mineral Density - ESTHER Study (2010)

N. Vujasinović Stupar, N. Milić, L. Petrović Lackov, N. Prodanović, M. Mijailović Ivković, Z. Grujić, Efficacy and Safety of Once Monthly Ibandronate Treatment in Patients with Reduced Bone Mineral Density - ESTHER Study, SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, Vol. 138, No. 1-2, pp. 56 - 61, 2010
Parathyroid Hormone Response to Vitamin D Insufficiency in Elderly Males With Chronic Heart Failure (2011)

B. Božić, G. Lončar, N. Prodanović, T. Lepić, Z. Radojčić, V. Čvorović, S. Dimković, B. Popović, Parathyroid Hormone Response to Vitamin D Insufficiency in Elderly Males With Chronic Heart Failure, Physiological research , pp. 155 - 163, 2011
Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure (2011)

G. Lončar, B. Božić, S. Dimković, N. Prodanović, Z. Radojčić, V. Čvorović, Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure, JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, pp. 78 - 85, 2011
Relationship of reduced cerebral blood flow and heart failure severity in elderly males (2011)

G. Lončar, B. Božić, S. Dimković, N. Prodanović, Z. Radojčić, V. Čvorović, Relationship of reduced cerebral blood flow and heart failure severity in elderly males, AGING MALE, pp. 59 - 65, 2011
A potential cross-talk between fat and bone in patients with chronic heart failure (2011)

G. Lončar, B. Božić, N. Prodanović, Z. Radojčić, N. Čvorović, S. Dimković, V. Popović, A potential cross-talk between fat and bone in patients with chronic heart failure, EUROPEAN HEART JOURNAL, pp. 32 - 609, 2011
Digital clubbing as an unusual comlication of the secondary hyperparathyroidism associated atypical neutrophils: a case report (2012)

N. Prodanović, Z. Špirić, G. Trninić, M. Erić, Digital clubbing as an unusual comlication of the secondary hyperparathyroidism associated atypical neutrophils: a case report, EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, pp. 98 - 102, 2012
Association od adiponetic with peripheral muscle status in elderly patients with heart failure (2013)

G. Lončar, B. Božić, S. Healing, N. Prodanović, V. Popović-Brkić, Association od adiponetic with peripheral muscle status in elderly patients with heart failure, EUROPEAN JOURNAL OF INTERNAL MEDICINE, pp. 10 - 10, 2013
A randomised,double-blind,parallel-group study to dmostrate eqivalence in afficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis:The PLANETRA study (2013-05)

D. Yoo, P. Hrycaj, P. Miranda, E. Ramiterre, M. Piotrowski, S. Shevchuk, V. Kovalenko, N. Prodanović, M. Abello-Banfi, S. Gutierrez-Ureña, L. Morales-Olazabal, M. Tee, R. Jimenez, O. Zamani, S. Lee, H. Kim, W. Park, U. Müller-Ladner, A randomised,double-blind,parallel-group study to dmostrate eqivalence in afficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis:The PLANETRA study, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, May, 2013
1. Osteoporoza u inflamatornim bolestima creva (2013-05)

N. Prodanović, 1. Osteoporoza u inflamatornim bolestima creva, STED Journal, Vol. 39, No. 1, pp. 149 - 156, May, 2013
FRI0281 The Rate of Positive Conversion in the Quantiferon- TB Gold Test over 2 Years among Patients Treated with CT-P13 or Innovator Infliximab in the Extension Studies of Planetas and Planetra (2014)

P. Wonung, D. Yoo, P. Hrycaj, N. Prodanović, S. Lee, FRI0281 The Rate of Positive Conversion in the Quantiferon- TB Gold Test over 2 Years among Patients Treated with CT-P13 or Innovator Infliximab in the Extension Studies of Planetas and Planetra, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2014
FRI0143 A radomized, double-blind, phase 3 study demonstrates clinical equivalence od CT-P13 to ifliximab when co-administered with methotrexate in patients with active rheumatoid arthritis (2014)

D. Yoo, P. Hrycaj, P. Miranda, E. Piotrowski, S. Shevchuk, V. Kovalenko, N. Prodanović, M. Abello-Banfi, S. Gutierrez-Ureña, L. Morales-Olazabal, M. Tee, R. Jimenez, O. Zamani, S. Lee, H. Kim, W. Park, U. Müller-Ladner, FRI0143 A radomized, double-blind, phase 3 study demonstrates clinical equivalence od CT-P13 to ifliximab when co-administered with methotrexate in patients with active rheumatoid arthritis, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2014
The Serbian Sokol club in Banja Luka (2015)

M. Prodanović, P. Pavlović, The Serbian Sokol club in Banja Luka, Physical Education and Sport through the centuries, Vol. 2, No. 1, pp. 32 - 53, 2015
BONE MARKERS IN MONITORING OF ANTIRESORPTIVE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS PATIENTS (2015)

T. Đopalić, N. Prodanović, B. Božić, BONE MARKERS IN MONITORING OF ANTIRESORPTIVE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS PATIENTS, Acta medica Medianae, Vol. 54, No. 3, pp. 5 - 11, 2015
SAT0152 A Randomised,Doble-Blind ,Phase III Study Comparing SB2,An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (2015-06)

J. Choe, N. Prodanović, j. Niebrizidovski, i. Staykov, E. Dokoupilova, A. Baranauskaite, R. Yatsyshyn, M. Mekić, W. Porawska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zielinska, J. Choe, Y. Rho, J. Smolen, SAT0152 A Randomised,Doble-Blind ,Phase III Study Comparing SB2,An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, Jun, 2015
FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud (2016)

J. Smolen, J. Choe, N. Prodanović, I. Staykov, E. Dokoupilova, A. Baranauskaite, R. Yatsyshyn, M. Mekić, W. Porawska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, Z. Lee, Y. Rho, FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2016
Efficacy and safety of CT- P13 (biosimilar infliximab) in patients with rheumatoid arthritis :Comparison betwen switching from reference infliximab to CT-P13 and continuing CT- P13 in the PLANETRA extension study (2016)

D. Yoo, N. Prodanović, J. Jaworski, P. Miranda, E. Ramiterre, A. Lanzon, A. Baranauskaite, P. Wiland, C. Abud-Mendoza, B. Oparanov, S. Smiyan, H. Kim, S. Lee, S. Kim, W. Park, Efficacy and safety of CT- P13 (biosimilar infliximab) in patients with rheumatoid arthritis :Comparison betwen switching from reference infliximab to CT-P13 and continuing CT- P13 in the PLANETRA extension study, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2016
Skeletal muscle status and its prognostic role in men with heart failure with reduced ejection fraction (Meeting Abstract) (2016)

G. Lončar, B. Božić, S. Healing, N. Prodanović, V. Popović-Brkić, Skeletal muscle status and its prognostic role in men with heart failure with reduced ejection fraction (Meeting Abstract), EUROPEAN HEART JOURNAL, pp. 10 - 10, 2016
3. Safety, immunogenecity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis:Results of a randomised, double-blind, phase III transation study (2017)

J. Smolen, J. Choe, N. Prodanović, Y. Rho, 3. Safety, immunogenecity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis:Results of a randomised, double-blind, phase III transation study, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2017
Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results (2017)

J. Smolen, J. Choe, N. Prodanović, J. Niebrizidovski, I. Staikov, E. Dokoupilova, A. Baranauskaite, R. Iatsishin, M. Mekić, V. Poravska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, I. Lee, I. Rho, Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results, RHEUMATOLOGY, pp. 10 - 10, 2017
Androgen status in non-diabetic elderly men with heart failure (2017)

G. Lončar, B. Božić, A. N, S. Nešković, N. Prodanović, V. Popović-Brkić, Androgen status in non-diabetic elderly men with heart failure, AGING MALE, pp. 10 - 10, 2017

Items

Efficacy and Safety of Once Monthly Ibandronate Treatment in Patients with Reduced Bone Mineral Density - ESTHER Study (2010)

Parathyroid Hormone Response to Vitamin D Insufficiency in Elderly Males With Chronic Heart Failure (2011)

Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure (2011)

Relationship of reduced cerebral blood flow and heart failure severity in elderly males (2011)

A potential cross-talk between fat and bone in patients with chronic heart failure (2011)

Digital clubbing as an unusual comlication of the secondary hyperparathyroidism associated atypical neutrophils: a case report (2012)

Association od adiponetic with peripheral muscle status in elderly patients with heart failure (2013)

A randomised,double-blind,parallel-group study to dmostrate eqivalence in afficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis:The PLANETRA study (2013-05)

1. Osteoporoza u inflamatornim bolestima creva (2013-05)

FRI0281 The Rate of Positive Conversion in the Quantiferon- TB Gold Test over 2 Years among Patients Treated with CT-P13 or Innovator Infliximab in the Extension Studies of Planetas and Planetra (2014)

FRI0143 A radomized, double-blind, phase 3 study demonstrates clinical equivalence od CT-P13 to ifliximab when co-administered with methotrexate in patients with active rheumatoid arthritis (2014)

The Serbian Sokol club in Banja Luka (2015)

BONE MARKERS IN MONITORING OF ANTIRESORPTIVE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS PATIENTS (2015)

SAT0152 A Randomised,Doble-Blind ,Phase III Study Comparing SB2,An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (2015-06)

FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud (2016)

Efficacy and safety of CT- P13 (biosimilar infliximab) in patients with rheumatoid arthritis :Comparison betwen switching from reference infliximab to CT-P13 and continuing CT- P13 in the PLANETRA extension study (2016)

Skeletal muscle status and its prognostic role in men with heart failure with reduced ejection fraction (Meeting Abstract) (2016)

3. Safety, immunogenecity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis:Results of a randomised, double-blind, phase III transation study (2017)

Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results (2017)

Androgen status in non-diabetic elderly men with heart failure (2017)